Ironwood Pharma (IRWD) Receives a Hold from Barclays

In a report released yesterday, Geoff Meacham from Barclays maintained a Hold rating on Ironwood Pharma (IRWD), with a price target of $16. The company’s shares closed yesterday at $12.78, close to its 52-week low of $12.67.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.0% and a 54.6% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and Gritstone Oncology Inc.

Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $17.17, a 34.4% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock with a $16 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.20 and a one-year low of $12.67. Currently, Ironwood Pharma has an average volume of 1.08M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient’s lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.